Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Association between plasma bilirubin and mortality

L Vitek, JA Hubacek, A Pajak, A Dorynska, M Kozela, L Eremiasova, V Danzig, D Stefler, M Bobak

. 2019 ; 18 (2) : 379-385.

Jazyk angličtina Země Mexiko

Perzistentní odkaz   https://www.medvik.cz/link/bmc20016949

Grantová podpora
NV15-28895A MZ0 CEP - Centrální evidence projektů

INTRODUCTION AND AIM: It has been proposed that plasma concentration of bilirubin, an endogenous antioxidant, is protective against diseases mediated by increased oxidative stress, including cardiovascular diseases (CVD) and cancer. To examine this hypothesis, we investigated the relationship between plasma bilirubin concentrations and bilirubin UDP-glucuronosyl transferase (UGT1A1) promoter gene variations (associated with increased bilirubin concentrations) with total/CVD and cancer mortality. MATERIALS AND METHODS: A nested case-control study was conducted within the Polish arm of the HAPIEE cohort. At baseline in 2002-2005, participants were examined in detail. Mortality follow-up (median (IQR) between blood draw and death was 3.7 (2.1-5.1) years) was performed by linkage with regional and national death registers. Plasma biomarkers were analysed in all subjects who died from any cause (cases, n=447) and in a random subsample of survivors (controls, n=1423). RESULTS: There was a strong negative association between plasma bilirubin levels and total and cancer mortality, expressed more profoundly in men. The adjusted OR of deaths from all causes and cancer, comparing the highest vs. lowest plasma bilirubin categories were 0.61 (95% CI: 0.42-0.87) and 0.39 (0.24-0.65), respectively. There was no association of bilirubin with CVD mortality. The UGT1A1*28 allele, a genetic marker of raised bilirubin, was also negatively associated with total/cancer mortality, although the associations were not statistically significant. DISCUSSION: Both the observational and genetic associations support the negative relationship between bilirubin and total mortality; this association appears to be driven by cancer mortality, while that with CVD mortality is not evident. Copyright © 2019 Fundacion Clinica Medica Sur, A.C. Published by Elsevier Espana, S.L.U. All rights reserved.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20016949
003      
CZ-PrNML
005      
20201119084329.0
007      
ta
008      
201029s2019 mx f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.aohep.2019.02.001 $2 doi
035    __
$a (PubMed)31054979
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a mx
100    1_
$a Vítek, Libor, $d 1969- $7 xx0035071 $u Institute of Medical Biochemistry and Laboratory Diagnostics, and 4th Department of Internal Medicine, 1st Faculty of Medicine, Charles University, Prague, Czech Republic. Electronic address: vitek@cesnet.cz.
245    10
$a Association between plasma bilirubin and mortality / $c L Vitek, JA Hubacek, A Pajak, A Dorynska, M Kozela, L Eremiasova, V Danzig, D Stefler, M Bobak
520    9_
$a INTRODUCTION AND AIM: It has been proposed that plasma concentration of bilirubin, an endogenous antioxidant, is protective against diseases mediated by increased oxidative stress, including cardiovascular diseases (CVD) and cancer. To examine this hypothesis, we investigated the relationship between plasma bilirubin concentrations and bilirubin UDP-glucuronosyl transferase (UGT1A1) promoter gene variations (associated with increased bilirubin concentrations) with total/CVD and cancer mortality. MATERIALS AND METHODS: A nested case-control study was conducted within the Polish arm of the HAPIEE cohort. At baseline in 2002-2005, participants were examined in detail. Mortality follow-up (median (IQR) between blood draw and death was 3.7 (2.1-5.1) years) was performed by linkage with regional and national death registers. Plasma biomarkers were analysed in all subjects who died from any cause (cases, n=447) and in a random subsample of survivors (controls, n=1423). RESULTS: There was a strong negative association between plasma bilirubin levels and total and cancer mortality, expressed more profoundly in men. The adjusted OR of deaths from all causes and cancer, comparing the highest vs. lowest plasma bilirubin categories were 0.61 (95% CI: 0.42-0.87) and 0.39 (0.24-0.65), respectively. There was no association of bilirubin with CVD mortality. The UGT1A1*28 allele, a genetic marker of raised bilirubin, was also negatively associated with total/cancer mortality, although the associations were not statistically significant. DISCUSSION: Both the observational and genetic associations support the negative relationship between bilirubin and total mortality; this association appears to be driven by cancer mortality, while that with CVD mortality is not evident.<ovid:br/><ovid:br/> Copyright &#xa9; 2019 Fundacion Clinica Medica Sur, A.C. Published by Elsevier Espana, S.L.U. All rights reserved.
650    02
$a senioři $7 D000368
650    12
$a bilirubin $x krev $7 D001663
650    02
$a biologické markery $x krev $7 D015415
650    12
$a kardiovaskulární nemoci $7 D002318
650    02
$a příčina smrti $7 D002423
650    02
$a ženské pohlaví $7 D005260
650    02
$a glukuronosyltransferasa $x genetika $7 D014453
650    02
$a lidé $7 D006801
650    02
$a mužské pohlaví $7 D008297
650    02
$a mendelovská randomizace $7 D057182
650    02
$a lidé středního věku $7 D008875
650    12
$a nádory $7 D009369
650    02
$a polymorfismus genetický $7 D011110
650    02
$a prediktivní hodnota testů $7 D011237
650    02
$a prognóza $7 D011379
650    02
$a promotorové oblasti (genetika) $7 D011401
650    02
$a hodnocení rizik $7 D018570
650    02
$a rizikové faktory $7 D012307
650    02
$a sexuální faktory $7 D012737
650    02
$a časové faktory $7 D013997
651    _2
$a Polsko $x epidemiologie $7 D011044
700    1_
$a Hubáček, Jaroslav, $d 1966- $7 nlk20050169367
700    1_
$a Pajak,A.
700    1_
$a Dorynska, A.
700    1_
$a Kozela, M.
700    1_
$a Eremiasová, L
700    1_
$a Danzig, V.
700    1_
$a Stefler, D.
700    1_
$a Bobak, M.
773    0_
$t Annals of Hepatology $x 1665-2681 $g Roč. 18, č. 2 (2019), s. 379-385 $p Ann Hepatol $w MED00172549
773    0_
$p Ann Hepatol $g 18(2):379-385, 2019 Mar - Apr $x 1665-2681
910    __
$a ABA008 $y p $z 0
990    __
$a 20201029102941 $b ABA008
991    __
$a 20201119084326 $b ABA008
999    __
$a ok $b bmc $g 1577156 $s 1107134
BAS    __
$a 3
BMC    __
$a 2019 $b 18 $c 2 $d 379-385 $x MED00172549 $i 1665-2681 $m Annals of hepatology
GRA    __
$a NV15-28895A $p MZ0
LZP    __
$a 2020-lp

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace